CERo Therapeutics Adds UC Davis Site to Phase 1 Blood Cancer Trial
CERo Therapeutics added UC Davis as a site for its Phase 1 CER-1236 trial in blood cancers.
Related stories
UniCredit Raises $3.5 Billion
M impact | EQUITY | Nov 14, 2026, 08:03 AM UTC
AMAT Shares Fall 2.58% as Headline Cites Record Q4 Revenue
The headline also says 2027 demand is seen above 30%, but provides no further context.
M impact | EQUITY | Nov 14, 2026, 08:02 AM UTC
MSCI to Drop MSTR; CEO Sees Low Impact; $6.8B Bitcoin Loss
M impact | EQUITY | Nov 14, 2026, 08:02 AM UTC
IndiGo Says Global Microsoft Service Disruption Is Fully Resolved
IndiGo said a global Microsoft service disruption affecting its email support services has been fully resolved.
M impact | EQUITY | Nov 14, 2026, 07:36 AM UTC
FAA Tech Failure Grounds Flights for Nearly Five Hours
Air travel ground to a halt for almost five hours Friday after an overloaded air traffic control system failed, snarling operations at Sea-Tac.
M impact | EQUITY | Nov 14, 2026, 07:32 AM UTC
Microsoft Restores Outlook and Teams After Global Outage
Microsoft says service to Outlook and Teams has been restored after a global outage.
M impact | EQUITY | Nov 14, 2026, 07:23 AM UTC